KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Resmed (RMD) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Resmed (RMD) over the last 16 years, with Q4 2025 value amounting to $8.5 billion.

  • Resmed's Liabilities and Shareholders Equity rose 1907.26% to $8.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $32.6 billion, marking a year-over-year increase of 1605.03%. This contributed to the annual value of $8.2 billion for FY2025, which is 1894.53% up from last year.
  • Per Resmed's latest filing, its Liabilities and Shareholders Equity stood at $8.5 billion for Q4 2025, which was up 1907.26% from $8.3 billion recorded in Q3 2025.
  • In the past 5 years, Resmed's Liabilities and Shareholders Equity registered a high of $8.5 billion during Q4 2025, and its lowest value of $4.6 billion during Q1 2021.
  • For the 5-year period, Resmed's Liabilities and Shareholders Equity averaged around $6.4 billion, with its median value being $6.7 billion (2023).
  • As far as peak fluctuations go, Resmed's Liabilities and Shareholders Equity surged by 4100.25% in 2022, and later soared by 149.96% in 2024.
  • Quarter analysis of 5 years shows Resmed's Liabilities and Shareholders Equity stood at $4.7 billion in 2021, then surged by 41.0% to $6.7 billion in 2022, then rose by 3.43% to $6.9 billion in 2023, then increased by 3.42% to $7.1 billion in 2024, then increased by 19.07% to $8.5 billion in 2025.
  • Its last three reported values are $8.5 billion in Q4 2025, $8.3 billion for Q3 2025, and $8.2 billion during Q2 2025.